The Resistance of Cervical Cancer to Chemotherapy and its Reversal. Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy Volume 9

The Resistance of Cervical Cancer to Chemotherapy and its Reversal provides a holistic understanding of cervical cancer development, immune-evading mechanisms of HPV, immunotherapies available, methods to study cervical cancer and the development of newer drugs. Content shows the involvement of signaling pathways during chemoresistance in cervical cancer, the involvement of genes in drug resistance, and introduces long noncoding RNAs as novel biomarkers.

In 10 chapters, this book first provides an introduction and history of cervical cancer; next, it discusses the influence of viruses on cervical cancer and finally, it describes therapies to overcome chemotherapy resistance in cervical cancer. This is the perfect reference to provide the fundamental base of knowledge needed for oncologists, pharmacologists, translational investigators, immunotherapists, scientists, and clinicians interested in building a comprehensive understanding of the field.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Role of Wnt/?-catenin signaling pathway in cervical cancer: Strategies to overcome therapeutic resistance
Targeting epigenetic regulatory machinery to overcome cervical cancer chemoresistance
The role of immune checkpoint proteins PD1 and PD-L1 during cancer resistance
Advancements in radiotherapy: transforming cervical cancer treatment
Pathogenesis of human papillomavirus induced carcinogenesis: insights on in vivo models and prophylactic strategies
Subcellular transport of epidermal growth factor receptor: diverse approaches in targeting epidermal growth factor receptor-driven cervical carcinoma
Structural insights into Human papillomavirus E6 and E7 oncoproteins: implications for drug design and therapeutic targeting
Critical insights to understand the underlying mechanisms in cervical cancer metastasis
Advancements of cytology in cervical cancer
Insights on molecular mechanisms of chemoresistance in cervical cancer
Computational techniques to study the cervical cancer
Advances in nanotechnology-based drug development and delivery for cervical cancer therapeutic strategies

Authors

S. Muthusami Associate Professor and Head, Cancer Research Centre, Karpagam Academy of Higher Education, Coimbatore, India. Dr. Sridhar Muthusami completed his Ph.D in endocrinology in the year 2011 from the University of Madras, India. His doctoral study was aimed at delineating the molecular mechanism underlying the anabolic actions of Cissus quadrangularis, an indigenous herb believed to exert anabolic effects on bone cells through IGFR. After completing his Ph.D, he has joined for his Postdoctoral work in the department of Radiation Oncology, Chungbuk National University, South Korea. He has worked on the role of Epidermal growth factor/receptor (EGF/EGFR) signaling and its regulation of oncoprotein Fused Toes Homolog (FTS) in cervical cancer cells from 2011 to 2014. He is also involved in the identifying the role of T0070907/EGCG/cordycepin on cervical cancer cells. Since 2015, he moved to the department of biochemistry, Karpagam Academy of Higher Education (Deemed to be University) and serving as Associate Professor and Head at Cancer Research Centre working in the area of development of EGFR TKIs for the treatment/management of cervical cancer/pancreatic cancer.

Table of Contents

Authors

Related Topics

Related Products

Immunotherapy in Oncology Market Report and Forecast 2025-2034

Adoptive Cellular Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2031

Immunotherapy for Neuroblastoma Market Report: Trends, Forecast and Competitive Analysis to 2031

Oncolytic Virus Immunotherapy Market - Global Strategic Business Report

Cellular Immunotherapy - Global Strategic Business Report